These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 21685865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Alemtuzumab in chronic lymphocytic leukemia.
    James DF, Kipps TJ.
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R, Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.
    Cancer; 2006 Nov 15; 107(10):2408-16. PubMed ID: 17054106
    [Abstract] [Full Text] [Related]

  • 10. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J.
    J Clin Oncol; 2007 Dec 10; 25(35):5616-23. PubMed ID: 17984186
    [Abstract] [Full Text] [Related]

  • 11. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S, Summers J, Keegan P, Pazdur R.
    Oncologist; 2008 Feb 10; 13(2):167-74. PubMed ID: 18305062
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T.
    BioDrugs; 2005 Feb 10; 19(1):9-22. PubMed ID: 15691213
    [Abstract] [Full Text] [Related]

  • 13. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR.
    Semin Oncol; 2006 Apr 10; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Hadj Tahar A.
    Issues Emerg Health Technol; 2005 Mar 10; (66):1-4. PubMed ID: 15806747
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.
    Oncogene; 2007 May 28; 26(25):3644-53. PubMed ID: 17530018
    [Abstract] [Full Text] [Related]

  • 16. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M, Schinkoethe T, Elter T.
    Cancer Invest; 2005 May 28; 23(6):488-96. PubMed ID: 16203656
    [Abstract] [Full Text] [Related]

  • 17. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E.
    Haematologica; 2007 Oct 28; 92(10):1367-74. PubMed ID: 17768114
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab (Campath 1-H).
    Schaal AD.
    Clin J Oncol Nurs; 2005 Oct 28; 9(5):630-2. PubMed ID: 16235592
    [Abstract] [Full Text] [Related]

  • 19. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
    Hillmen P.
    Semin Oncol; 2006 Apr 28; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
    [Abstract] [Full Text] [Related]

  • 20. Antibody therapy for chronic lymphocytic leukemia.
    Christian BA, Lin TS.
    Semin Hematol; 2008 Apr 28; 45(2):95-103. PubMed ID: 18381104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.